Answers are grounded in this paper and cite their sources.
Retrospective analysis reveals HER2 status and pathological traits in gastric cancer, highlighting diagnostic implications in high-incidence regions.
A retrospective analysis was conducted on the positive rate of HER2 in gastric cancer in the Chinese high-incidence area of Wuwei from 2015 to 2024. The pathological characteristics of HER2-positive gastric cancer were explored to provide a basis for precise diagnosis and treatment in high-incidence areas of gastric cancer. A retrospective study design was adopted to collect and analysis the HER2 expression status of gastric cancer surgical specimens from 2015 to 2024. A total of 416 gastric cancer surgical specimens were collected for HER2 detection, and the positive rate of HER2 was 9.13% (38/416), including 33 males (9.68%) and 5 females (6.67%), with no statistical significance ( P >.05). There were 24 (8.63%) HER2 positive patients over 60 years old, 11 (10.67%) HER2 positive patients between 50 and 59 years old, and 3 (8.6%) HER2 positive patients under 50 years old, with no statistical significance ( P >.05). In cTNM stages, HER2 was positive in 7 patients (5.65%) in stage Ⅰ, 16 patients (10.32%) in stage Ⅱ, 14 patients (10.61%) in stage Ⅲ, and 1 patient (20%) in stage Ⅳ, with no statistical difference between groups ( P >.05). The positive rate of tubular adenocarcinoma HER2 in WHO classification was 10.5%. Other tissue types were 0%, there were differences ( P <.05); The positive rate of HER2 in well-differentiated adenocarcinoma was 10.84%, in moderately differentiated adenocarcinoma 16.44%, and in poorly differentiated adenocarcinoma 8.25%, with a difference between moderately and poorly differentiated adenocarcinoma ( P <.05). The positive rate of HER2 in T3 infiltration depth was 15.97% higher than that in T1/T2/T4 ( P <.05). The positive rate of HER2 in cardiac/fundus was 16.26% higher than that in other sites ( P <.05). The proportion of patients with intestinal stype gastric cancer was the largest in Lauren classification (59.13%), but the HER2 positive rate of mixed type was significantly higher than that of other Lauren classification ( P <.001). Patients with lymph node metastasis (13%) were significantly higher than those without lymph node metastasis (4.66%), and the difference was statistically significant ( P <.01). The research data indicate that correlation between the expression of HER2 in areas with a high incidence of gastric cancer and the pathological characteristics.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: